Compound class:
Antibody
Comment: DX-2507 is a fully human anti-FcRn monoclonal antibody [2] that was originally developed by Dyax Corporation, and is being progressed by Shire following their acquisition of Dyax.
A X-ray crystal structure of DX-2507-Fab in complex with FcRn has been published [1]. The Protein Data Bank identifier for the 2.15Å structure of unbound DX-2507-Fab is 5WHJ. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| Bioactivity Comments |
| DX-2507 binds IgG throughout the endocytic/exocytosis cycle both in the endosome at acidic pH and at the cell surface at neutral pH [2]. It depletes IgG in monkeys by >60% following two subcutaneous injections [2]. DX-2507 does not disrupt serum albumin binding to FcRn. It does not induce hypogammaglobulinemia and has no effect on other classes of antibodies. Nor does DX-2507 disrupt the primary response to novel antigen. All indications are that DX-2507-mediated FcRn antagonism has little implication with regards to general immune system disruption or infection risk. |
| Selectivity at other protein targets | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
